Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom
Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the ...
Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the ...
[mailpoet_form id=”1″]
© 2022. All Right Reserved By Moneyoutlook.com